J Pediatr Intensive Care 2020; 09(02): 139-140
DOI: 10.1055/s-0039-1700951
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Levetiracetam Treatment-Associated Acute Rhabdomyolysis in an Adolescent

1   Department of Pediatrics, Division of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Dincer Yildizdas
1   Department of Pediatrics, Division of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Behruz Huseyınlı
1   Department of Pediatrics, Division of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Ozden Ozgur Horoz
1   Department of Pediatrics, Division of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Gulen Gul Mert
2   Department of Pediatrics, Division of Pediatric Neurology, Cukurova University Faculty of Medicine, Adana, Turkey
,
Faruk Ekinci
1   Department of Pediatrics, Division of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Duygu Ozcanyuz
2   Department of Pediatrics, Division of Pediatric Neurology, Cukurova University Faculty of Medicine, Adana, Turkey
› Author Affiliations
Further Information

Publication History

09 October 2019

23 November 2019

Publication Date:
14 January 2020 (online)

Abstract

Etiology of rhabdomyolysis includes hereditary muscle enzyme deficiencies, trauma, viral infections, excessive exercise, hypothyroidism, and medications such as colchicine, lithium, and statins. Several studies have reported that various antiepileptic drugs may induce rhabdomyolysis. Levetiracetam is one of the antiepileptic drugs implicated in the etiology of rhabdomyolysis. Herein, we present a case of rhabdomyolysis in an adolescent treated with levetiracetam. We wanted to draw attention to the increasing trend of levetiracetam-associated rhabdomyolysis frequency in pediatric patients.